Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. It operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The company offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. It also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, the company provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. It provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Elevance Health Inc.

Evolva Holding ( ($CH:EVE) ) has issued an update. Shareholders of EvoNext Holdings SA approved all board proposals at the 2026 Annual General Meet...

EvoNext Wins Shareholder Backing for Governance Changes to Pursue Reverse Takeover

Electrovaya Inc. (($TSE:ELVA)) has held its Q2 earnings call. Read on for the main highlights of the call. Electrovaya Inc. delivered an upbeat ear...

Electrovaya Inc. Earnings Call Signals Profitable Growth

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Molecular Partners (MOLN), Enliven Therapeutics (ELV...

Analysts Are Bullish on Top Healthcare Stocks: Molecular Partners (MOLN), Enliven Therapeutics (ELVN)

There’s a lot to be optimistic about in the Industrial Goods sector as 2 analysts just weighed in on Electrovaya (ELVA) and Vertiv Holdings (VRT) w...

Analysts Offer Insights on Industrial Goods Companies: Electrovaya (ELVA) and Vertiv Holdings (VRT)

An announcement from Elevance Health ( ($ELV) ) is now available. On May 13, 2026, Elevance Health, Inc. shareholders held their annual meeting, wh...

Elevance Health Shareholders Back Directors, Pay and Auditor

Elevra Lithium ( ($AU:ELV) ) just unveiled an update. Elevra Lithium Limited has lodged an Appendix 3B with the ASX detailing a proposed issue of u...

Elevra Lithium Plans 145 Million Convertible Notes Issue

The latest update is out from Elevra Lithium ( ($AU:ELV) ). Elevra Lithium Limited has notified the ASX of a proposed securities issue comprising u...

Elevra Lithium Plans New Share and Option Issue to Bolster Funding

The latest announcement is out from Elevra Lithium ( ($AU:ELV) ). Elevra Lithium Limited has outlined plans for a significant capital raise via a c...

Elevra Lithium Plans Capital Raise via Placement and Securities Purchase Plan

Elevra Lithium ( ($AU:ELV) ) just unveiled an update. Elevra Lithium has released an updated scoping study for expanding its North American Lithium...

Elevra Lithium doubles NAL expansion value with staged growth plan

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Enliven Therapeutics (ELVN), Molina Healthcare (MO...

Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN), Molina Healthcare (MOH) and Aldeyra Therapeutics (ALDX)

The latest announcement is out from Elevra Lithium ( ($AU:ELV) ). Elevra Lithium has agreed to sell its entire interest, including offtake rights, ...

Elevra Sells Ghana Ewoyaa Stake to Refocus on North American Lithium Assets

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Entrada Therapeutics Inc (TRDA), Edgewise Therapeu...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Entrada Therapeutics Inc (TRDA), Edgewise Therapeutics (EWTX) and Elevance Health (ELV)

Analysts are intrested in these 5 stocks: ( ($MELI) ), ( ($TMUS) ), ( ($CRBP) ), ( ($CLS) ) and ( ($ELV) ). Here is a breakdown of their recent


MercadoLibre, T-Mobile, Corbus, Celestica, Elevance Trending With Analysts

Elevra Lithium ( ($AU:ELV) ) has issued an update. On April 28, 2026, Elevra Lithium Limited announced that 255,830 ordinary fully paid shares woul...

Elevra Lithium Lists New Shares Tied to Piedmont Merger Equity Awards on ASX

An update from Evolva Holding ( ($CH:EVE) ) is now available. EvoNext Holdings SA has released its 2025 full-year report, showing liquidity of CHF ...

EvoNext posts low 2025 cash burn as it pursues reverse takeover and eyes arbitration upside

Elevra Lithium ( ($AU:ELV) ) just unveiled an update. Elevra Lithium Limited has applied for quotation on the ASX of 255,830 new ordinary fully pai...

Elevra Lithium Seeks ASX Quotation for Additional Ordinary Shares

Macquarie analyst maintained a Buy rating on Elevra Lithium today and set a price target of A$11.60. In a report released on April 24, Canaccord Ge...

Market Cap	$87.36B	P/E Ratio	14.41
52W High	$408.00	52W Low	$273.71
Div Yield	688.0%	Payout Ratio	29.0%
EPS Growth 3Y	N/A	52W Position	85.0%
Overall Score	72	Value Score	100
Quality Score	50	Technical Score	66

EPS Current Est	$26.91	EPS Next Est	$29.17
EPS Growth Est	+8.4%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ELV	$387.85	-1.73%	1.52M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ELV	$387.85	-1.7%	1.52M
3
4
5
6

ELV

ELV

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Elevance Health Inc. Data in Excel

Get Elevance Health Inc. Data in Excel